Context: An expert opinion perspective on why osteoporosis is underdiagnosed and
undertreated. Objective: To highlight the potential reasons for why osteoporosis is …

Context Prolonged bisphosphonate (BP) treatment for osteoporosis prevents hip and other
fractures but causes atypical femoral fractures (AFF). Objective To establish the relationship …

Although there is strong evidence that bisphosphonates prevent certain types of
osteoporotic fractures, there are concerns that these medications may be associated with …

Background: Studies suggest an increasing occurrence of atypical femoral fractures with the
use of bisphosphonates. Objective: To examine whether the use of bisphosphonates …

Bisphosphonates (BPs) are highly effective in treating osteoporosis and reducing hip,
vertebral, and other fractures by as much as 50% to 70%. However, since 2006, atypical …

Bisphosphonates are a mainstay of therapy for osteoporosis. Several studies have
documented their efficacy in preventing both vertebral and nonvertebral fractures. 1–4 With …

Considerable data and media attention have highlighted a potential “crisis” in the treatment
of osteoporosis. Specifically, despite the availability of several effective drugs to prevent …

Osteoporosis: how long should we treat? : Current Opinion in Endocrinology, Diabetes and
Obesity Osteoporosis: how long should we treat? : Current Opinion in Endocrinology …

Osteoporosis, a skeletal disorder characterized by reduced bone strength that predisposes
to an increased risk of fracture, affects 10 to 12 million people in the United States. In 2000 …

Background Bisphosphonates are effective in reducing hip and osteoporotic fractures.
However, concerns about atypical femur fractures have contributed to substantially …